Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT05165316Enrolling By Invitation

European Long-acting Antipsychotics in Schizophrenia Trial-II

Role: lead

NCT02597439Phase 4Completed

Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

Role: lead

NCT01248195Phase 4Completed

Optimization of Treatment and Management of Schizophrenia in Europe

Role: lead

All 3 trials loaded